ICU Medical Inc./DE (ICUI) is a global medical device company that specializes in the development, manufacture, and sales of innovative medical devices used in vascular therapy, critical care, and oncology applications. The company is named after its founder, Dr. George A. Lopez, who invented the first "disposable medical connector" while working as an intern in the intensive care unit (ICU), which is where the company's name - ICU Medical - originated.
Founded in 1984 and headquartered in San Clemente, California, the company primarily creates products that enhance patient outcomes by helping to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs.
ICU Medical Inc.'s product line includes the Clave, a needle-free connection device designed to maintain a closed system during the administration of IV therapy. It also offers intravenous catheters, closed-system transfer devices for hazardous drugs, and custom infusion sets. Additionally, ICU Medical Inc. provides products for patient monitoring, such as disposable pressure transducer systems and hemodynamic monitoring systems.
ICUI is well known for its consistent focus on improving and simplifying the infusion therapy process, ensuring safety for both patients and healthcare professionals. For instance, its closed system transfer device, the ChemoLock and ChemoClave systems, are designed to prevent exposure to hazardous drugs during drug preparation, administration, and disposal, improving the safety of healthcare workers who frequently handle these medications.
One of the company's landmark achievements was in 2016, when it purchased the Hospira Infusion Systems business from Pfizer for $1 billion. This acquisition extended ICU Medical's product offering to include IV pumps and solutions, further validating its commitment to becoming a comprehensive player in the IV therapy market.
Today, ICU Medical Inc. is among the leaders in its field, securing its position in the healthcare sector with its commitment to innovation, patient safety, and superior product quality. The steadfast focus on research and development, along with strategic acquisitions and partnerships, has propelled ICU Medical Inc. to continued success, reflected in its robust market presence and stellar reputation in the medical device industry.
Furthermore, ICU Medical Inc./DE believes in fulfilling its corporate responsibility by committing to sustainable practices that consider the environment, their employees, and society. These efforts incorporate everything from transparency in their manufacturing and operational processes to employee welfare and community outreach programs.
With the ongoing COVID-19 pandemic further emphasizing the need for secure and efficiency-driven healthcare solutions, ICU Medical Inc./DE is positioned even more firmly to respond to these challenges. Their products and solutions are at the forefront of delivering safe and effective medical care - a testament to their determination in setting new standards in healthcare delivery and patient safety.